IP Library › Granted Patent US 10,294,224
Granted Patent B2
US 10,294,224 · App. 15/532,281 · Granted May 21, 2019

Lyophilized composition of a diazabicyclooctane compound and process of producing the same

Inventors: Takaya Ogawa (Kanagawa, JP); Takuya Yokoyama (Kanagawa, JP); Shusuke Furuyama (Kanagawa, JP); Masato Ichiki (Kanagawa, JP); Kenichi Fushihara (Kanagawa, JP)
Assignee: MEIJI SEIKA PHARMA CO., LTD.
C07D471/08A61K9/0019A61K9/19A61K31/439A61K47/02C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,294,224
App. No.
15/532,281
Granted
May 21, 2019
Kind
B2
Abstract

A process for producing crystals of a compound represented by the following formula (I): by crystallizing the compound from an aqueous solution containing the compound and an inorganic salt, such as sodium chloride. Such crystals can be subjected to lyophilization to provide a lyophilized composition having a desirable storage stability.

Claims (11)

1. A process for producing a lyophilized composition comprising crystals of a compound represented by the following formula (I):

the process comprising crystallizing said compound by subjecting an aqueous solution containing said compound and a salt to lyophilization, the salt being selected from the group consisting of an inorganic salt that is amenable to be added to a parenteral injection, tetrabutyl ammonium bromide, sodium acetate, sodium citrate, sodium tartrate, sodium glutamate and potassium sodium tartrate, wherein the crystals of the compound of formula (I) are crystalline form I having characteristic peaks appearing at a lattice spacing (d) of 7.34, 5.66, 5.53, 5.30, 5.02, 4.66, 4.37, 4.28, 4.06, 3.68, 3.62, 3.47, 3.36, 3.30, 3.16, 3.11, 3.03, 2.99 and 2.50 Å in a powder X-ray diffraction pattern.

2. The process according to claim 1 , wherein the aqueous solution containing said compound and the salt is obtained by dissolving said compound and the salt together in water, or by dissolving either of said compound or the salt in water and then dissolving the other of said compound or the salt in the resultant solution.

3. The process according to claim 1 , wherein no heat treatment or refreezing of a resultant frozen product is performed.

4. The process according to claim 1 , wherein the salt is the salt, and the salt is sodium chloride.

5. A lyophilized composition comprising crystals of a compound represented by the following formula (I):

and a salt selected from the group consisting of an inorganic salt that is amenable to be added to a parenteral injection, tetrabutyl ammonium bromide, sodium acetate, sodium citrate, sodium tartrate, sodium glutamate and potassium sodium tartrate, wherein the crystals of the compound of formula (I) are crystalline form I having characteristic peaks appearing at a lattice spacing (d) of 7.34, 5.66, 5.53, 5.30, 5.02, 4.66, 4.37, 4.28, 4.06, 3.68, 3.62, 3.47, 3.36, 3.30, 3.16, 3.11, 3.03, 2.99 and 2.50 Å in a powder X-ray diffraction pattern.

6. The lyophilized composition according claim 5 , wherein the salt is the inorganic salt, and the inorganic salt is sodium chloride.

7. The process according to claim 1 , wherein said compound is crystallized by adding a poor solvent to the aqueous solution containing said compound and the salt.

8. The lyophilized composition according to claim 5 , wherein the salt is the inorganic salt, and the inorganic salt is sodium chloride.

9. The process according to claim 7 , wherein the poor solvent is an alcohol.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2017
From: OGAWA, TAKAYA; YOKOYAMA, TAKUYA; FURUYAMA, SHUSUKE; ICHIKI, MASATO; FUSHIHARA, KENICHI
To: MEIJI SEIKA PHARMA CO., LTD.
Reel/Frame 042565/0037 →
Priority Claims (1)
JP 2014-246425 · Dec 5, 2014 · national
Continuity (1)
Related Publication 20170327499A1 · Nov 16, 2017
Cited By (1)
US 12,221,443